LDI Research Seminar with Scott Ramsey, MD, PhD
“Financial Toxicity: An Emerging Concept and Consequence of Cancer Care”
Dr. Ramsey is a general internist and health economist. He is a Full Member in the Cancer Prevention Program, Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, where he directs Hutchinson Institute for Cancer Outcomes Research, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the School of Medicine, School of Pharmacy, and the Institute for Public Health Genetics at the University of Washington.
Trained in Medicine and economics, Dr. Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs, and cost-effectiveness of treatments for lung, colorectal, and prostate cancer. His research portfolio and interests include: large scale SEER-Medicare/Cancer Registry data linkages, patient reported outcomes, economic modeling of health care interventions, cost-effectiveness analysis, quality of life assessment, patterns of care, health care utilization, economic burden of disease for patients and society, pragmatic trial design, early technology assessment, and stakeholder engagement.
Ongoing and recent research projects include (1) an NCI study partnering with the Southwest Oncology Group to bring comparative effectiveness principles to cooperative group trials, (2) examining bankruptcy among persons with cancer, (3) developing a genetic screening policy model for colorectal cancer, (4) evaluating decision making for men newly-diagnosed prostate cancer, (5) investigating cancer screening, incidence, treatment, and outcomes for Native Americans diagnosed with cancer, and (5) within the context of a clinical trial, evaluating the economic impact of bone marrow transplant from the perspective of patients and families, health insurers, and society.
Dr. Ramsey is co-Chair of the Outcomes and Comparative Effectiveness Committee of the Southwest Oncology Group, past President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the IOM Cancer Policy Forum.